In recent years, the role of T cells, dentritic antigen presenting cells (APCs) and cytokine network in inflammatory dermatoses has been more completely understood. This in turn has enabled the completion of new potentials and goals in immunotherapy. As research in Immunodermatology increased, newly targeted treatments for immunodisfunction were also developed. These treatments were not only beneficial for the patient, but also created experimental tools for better understanding disease pathophysiology and for rethinking nosology. In Dermatology, especially psoriasis treatment, targeted biologic treatment methods have been developed. Immunobiologic treatments can be defined by the therapeutic agents produced by the organisms by using recombination biotechnology. This article will briefly discuss the general characteristics of immunobiologic agents.